Physician profile
Mindyn Brown
NPI 1982296125
$2,648.75
in general payments reported to CMS, 2019-2025
23 companies · $793 in 2025
The $793 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $367 · 2023: $700 · 2024: $788 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $456.96 | 2023-2024 | Evenity, Krystexxa, Prolia |
| Abbvie INC. | $448.75 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $355.47 | 2024-2025 | Stelara, Remicade, Tremfya |
| Janssen Biotech, INC. | $287.61 | 2024-2025 | Tremfya, Stelara |
| Horizon Therapeutics Plc | $181.98 | 2023 | Tepezza, Krystexxa |
| Eisai INC. | $172.28 | 2025 | |
| Alexion Pharmaceuticals, INC. | $132.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.79 | 2025 | Entyvio |
| Tg Therapeutics, INC. | $89.81 | 2024 | |
| Argenx US, INC. | $65.18 | 2022 | |
| Lilly USA, LLC | $50.18 | 2022-2025 | Omvoh |
| Lundbeck LLC | $44.31 | 2024-2025 | Vyepti |
| Biogen, INC. | $31.46 | 2025 | Tysabri |
| Octapharma USA, INC. | $31.27 | 2023 | Panzyga |
| Tela Bio, INC. | $29.24 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $24.63 | 2022 | |
| Davol INC. | $23.27 | 2022 | |
| Sk Life Science, INC. | $21.05 | 2022 | |
| Neurocrine Biosciences, INC. | $20.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.68 | 2022 | |
| Averitas Pharma INC. | $16.16 | 2025 | Qutenza |
| Myriad Genetic Laboratories, INC. | $14.69 | 2022 | |
| Genentech USA, INC. | $14.41 | 2024 | Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindyn Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.